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Microbial resistance to chemotherapy has caused countless deaths where malaria is endemic.
Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant
parasites. Here we use a diverse set of antimalarial compounds to investigate the acquisition
of drug resistance and the degree of cross-resistance against common resistance alleles.
We assess cross-resistance using a set of 15 parasite lines carrying resistance-conferring
alleles in pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA
synthetase or hsp90. Subsequently, we assess whether resistant parasites can be obtained
after several rounds of drug selection. Twenty-three of the 48 in vitro selections result in
resistant parasites, with time to resistance onset ranging from 15 to 300 days. Our data
indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial
candidates, and focusing our attention on fast-killing compounds may result in a slower onset
of clinical resistance.
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M
alaria remains a devastating disease, with an estimated
198 million cases (uncertainty range 124–283 million)
and 584,000 deaths (uncertainty range 367,000–
755,000) in 2013 alone, affecting primarily children under the
age of ﬁve1. Given that the current vaccine available provides only
moderate protection2, chemotherapeutics constitute the best
clinical tools available for the prevention and treatment of
malaria. Currently, A number of effective drug therapies exist,
most of which target the malaria parasite during its replicative
cycle within human erythrocytes, the lifecycle stage that
is associated with clinical manifestations of malaria3. These
consist of 4-aminoquinolines including chloroquine, piperaquine
and related compounds; antifolates such as pyrimethamine
and cycloguanil; alkanolamines such as halofantrine and
lumefantrine; endoperoxides such as artesunate, artemisinin and
artemether; and newer synthetic compounds. Antimalarial
treatments are typically administered as combination therapies,
and artemisinin-based combination therapies (ACTs, such as
artemether-lumefantrine) currently represent the therapy class
that is most effective and that is the standard of care
recommended by the World Health Organization (WHO).
While ACTs have been a highly effective frontline therapy,
particularly against multidrug-resistant Plasmodium falciparum
infections, there is now evidence of resistance emerging to
artemisinin and its derivatives4–7. Clinical trials with artemisinin
mono-therapies have shown that these compounds are taking
considerably longer to clear malaria infections in Southeast
Asia—typically twice as long as observed a decade ago. Given that
parasites have already acquired resistance to several partner
drugs, treatment failures are beginning to be observed with
combination therapies8,9. Thus, new compound classes, ideally
with new mechanisms of action, are urgently needed if the gains
of the last decade are to be sustained.
In anticipation of eventual widespread ACT failure, there
has been a focused and coordinated effort to place new
antimalarial drug candidates into the drug development pipeline
(see http://www.mmv.org/research-development/rd-portfolio).
Leads from phenotypic screens in particular are being progressed
into molecules that are suitable for testing in clinical trials.
An open question, however, is whether small molecules from
phenotypic screens will lead to the identiﬁcation of new druggable
targets and pathways that do not rapidly lose effectiveness in the
ﬁeld because of acquired and pre-existing parasite resistance.
Here we use a set of 50 antimalarial compounds identiﬁed
in phenotypic screens10–13 to systematically evaluate whether
resistant parasites can be selected and whether or not pre-existing
resistance mechanisms confer resistance using a panel of strains
containing mutations in a variety of genes, including
P. falciparum cyclic amine resistance locus (pfcarl)14,
cytochrome bc1 (refs 15–17) and P. falciparum ATPase 4
(pfatp4)18–20. Here we show that pre-existing resistance is less
likely to be a problem but that the de novo acquisition of
resistance occurs rapidly for many compounds. We highlight a set
of antimalarial compounds that have thus far deﬁed attempts to
create drug-resistant parasites in a variety of different laboratories
and identify features that are shared by all, including a rapid rate
of killing and lack of pre-existing resistance.
Results
Initial selection of compounds. To systematically investigate
both the de novo acquisition and pre-existing landscape of drug
resistance, we assembled a set of 50 diverse compounds selected
from P. falciparum asexual phenotypic screens10–13. Compounds
were initially chosen based on potency, demonstrated by activity
against asexual blood stages ranging from 23 nM to 1.67 mM EC50
with most compounds having an EC50 of o1mM in the
P. falciparum strain 3D7 as measured by a hypoxanthine
incorporation assay. To minimize non-novel pharmacophores,
compounds were compared against the scaffolds of clinical
antimalarials, eliminating candidates with similar structures.
Compounds in our set ranged in molecular weight from 261
to 574 g mol 1, with 42 compounds having drug-like properties
(compliant with Lipinski’s rule of ﬁve) and the remaining
8 identiﬁed as probe-like compounds. We sought to maximize
chemical diversity in our set by eliminating similar compounds
as indicated by the Tanimoto coefﬁcient, since compounds
with Tanimoto coefﬁcients 40.85, a quantitative measurement
of chemical scaffold similarity, are thought to have similar
biological activity to one another21,22. The resulting compound
set displayed an average Tanimoto coefﬁcient of 0.186,
ranging from 0.093 to 0.923 (Fig. 1). Although a few
compounds were similar to one another (particularly two
carbazoles: MMV009063 and MMV665882) a majority of the
set was diverse, possessing a variety of functional groups and
heterocyclic substructures.
Compound evaluation against a panel of resistant clones.
Multidrug resistance alleles, including mutations in P. falciparum
chloroquine resistance transporter (pfcrt) and P. falciparum
multi-drug resistance transporter 1 (pfmdr1) are very common in
ﬁeld isolates. Therefore, we sought to assess the degree to which
pre-existing resistance alleles would contribute to a loss of
potency for this diverse collection of small molecule compounds.
Fifteen clones derived from three main parent lines were chosen
to maximize diversity in mutated pathways and genetic
backgrounds, thus representing the variety of resistance seen in
the ﬁeld: 3D7 (ref. 23), W2 (ref. 24) or Dd2 (ref. 25). The 3D7 line
originates from the clone of a Netherlands clinical isolate
strain23,26 and is generally considered to be drug sensitive,
though it does convey resistance to sulfadoxine. Conversely, W2
(ref. 24,27) and Dd2 (ref. 25) are multi-drug-resistant lines
originating from the Indochina III/CDC isolate, which contain
point mutations in pfcrt as well as ampliﬁcations in pfmdr1 and
GTP cyclohydrolase27.
A total of nine known drug-resistance genes were represented
by our strain set, containing validated critical single nucleotide
variants (SNVs) or copy number variants as well as a handful of
additional background mutations. One strain, TM90C2A, was a
clinical isolate from Thailand28, while the remaining 15 lines were
created through in vitro evolution. Clones contained one or more
resistance-conferring alleles in the folate pathway28, pfcrt (ref. 29),
P. falciparum dihydroorotate dehydrogenase (pfdhodh)30,
pfcarl (ref. 14), prolyl t-RNA synthetase31 or heat shock protein
90 (hsp90). We also investigated multiple cytochrome
bc1 (refs 15–17) and pfatp4 (refs 18–20) alleles, including three
alleles in the cytochrome bc1 Qo site, which confer resistance
to atovaquone15 or a tetracyclic benzothiazepine16 and one
allele in the cytochrome bc1 Qi site conferring resistance
to a benzylsulfonamide17. The ﬁve PfATP4 mutant lines
possess alleles that map to the transmembrane channel of
the sodium-dependent ATP4 transporter, and were acquired
by exposing parasites to sub-lethal concentrations of a
spiroindolone18, an aminopyrazole19, or other scaffolds from
the Tres Cantos Antimalarial Set library20. These two resistance
genes were represented by multiple strains since critical SNV
mutations may be located within an active site or result in a
change in membrane potential, resulting in each mutation only
affecting a subset of PfATP4 or cytochrome bc1 inhibitors.
To evaluate potential overlapping activity against known
antimalarial drug targets, we performed dose-response studies
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with each compound against our assembled set of drug-resistant
lines and their corresponding parents, in an asexual blood
stage proliferation assay (Table 1). Comparisons were made to the
drug-sensitive strain 3D7 when a parent was unavailable
(TM90C2A, W2 and Dd2). As laboratories conducted EC50
assays with different strains and protocols, all comparisons were
made between assays from the same laboratory and under the
same assay conditions. Compounds displaying 45-fold EC50
shifts relative to the parent or sensitive strain were ﬂagged as
having potentially non-novel targets. Average fold shifts per
strain ranged from 0.82 to 2.34, with a median of 1.23 indicating
there was not common resistance to any one resistant clone.
No resistance patterns were observed when classifying the
compounds based on chemical structure, but this was not
surprising given the diversity of compounds chosen. On the other
hand, given that these conﬁrmed compounds were derived
from larger unconﬁrmed hit lists to which some ﬁltration criteria
may have been applied (for example, elimination of obvious
dihydrofolate reductase inhibitors32), some10–13 pre-existing bias
may exist in the set.
Alleles in the strain set generally did not confer resistance to
the vast majority of the compounds (Fig. 2a), with only
two compounds (MMV019066 and MMV008149) losing
efﬁcacy in some resistant lines relative to their parent clones
(EC50 fold-shifts 45-fold). ATQ-R4, bearing a Qo cytochrome
bc1 allele, was resistant to a propanamide, MMV019066,
(P value¼ 0.0016) with an EC50 fold-shift of 16 , as determined
by a one-way analysis of variance (ANOVA) analysis with
a Dunnett’s multiple comparison correction. In addition,
CYTb-G131S, a cytochrome bc1 Qo allele, demonstrated complete
resistance to MMV008149, a carboxamide, with a 438-fold
change in EC50. Statistically signiﬁcant resistance was seen against
MMV019066 and MMV008149 in other cytochrome bc1 Qo
mutants (ATQ-R5 and ATQ-R4, respectively), but the EC50
fold-shifts seen were under the threshold value set for the study.
Neither compound shared any structural features with other
cytochrome bc1 inhibitors, including atovaquone and decoquinate
(Fig. 2b).
As had been previously observed19, mutations in PfATP4
















































































































































































































































































































































































































































Figure 1 | Chemically diverse compound set. Hierarchical clustering of the 50 compound set. Compounds were clustered by a maximum substructure
similarity Tanimoto coefﬁcient. In vitro selections that were successful in yielding resistant parasites are highlighted in blue, whereas compounds where
resistance development was unsuccessful are highlighted in dashed red.
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compounds: ATP4-Mut2 exhibited sensitivity to a sulfonamide
(MMV009108—P value¼ 0.0001; 23 fold-shift) and a
carboxamide (MMV028038—P value¼ 0.0007; 5 fold-shift).
ATP4-Mut3 additionally conferred sensitivity to MMV009108
(P value¼ 0.0047; 5.2 fold-shift). Neither compound was
structurally similar to spiroindolones, pyrazoles or
dihydroisoquinolones, all previously identiﬁed PfATP4
inhibitors (NITD609 (ref. 18), KAE678 (ref. 18), GNF4492
(ref. 19) and (þ )-SJ733 (ref. 20)), with a Tanimoto coefﬁcient
range of 0.127–0.34 (Fig. 2c).
Finally, two compounds (MMV665939 and MMV028895) lost
efﬁcacy in the parent strains W2 or Dd2 when compared with
the 3D7 sensitive strain within the same lab. MMV665939
demonstrated fold shifts in W2 compared with 3D7 (EC50 fold-
shift—9.5 ), as well as in the other two W2-based clones
(PfATP4-Mut1: 16.6 , PfATP4-Mut2: 18.9 ) compared with
3D7. Fold shifts in Dd2 compared with 3D7 were also seen in
MMV665939, though these shifts were less severe (1.5–3.1 ;
average 2.4 ). MMV028895 showed reduced efﬁcacy in Dd2
(EC50 fold-shift 7.1 ), which was also seen throughout the other
Dd2 clones (2.0–7.5 ; average—5.5 ), but unlike MMV665939
maintained potency against W2 strains. These efﬁcacy changes in
Dd2 and W2 are most likely due to pfmdr, given that W2 and
Dd2 contain additional copies of the multi-drug resistance gene
(2 and 3–4 copies, respectively) when compared to 3D7.
Selection of resistant parasites. While we found an overall lack
of pre-existing resistance, analysing the onset of resistance was
critical, as compounds resulting in rapid resistance are not ideal
for clinical development. We therefore sought to create drug-
resistant parasites using a variety of different selection methods.
We implemented either a high-dose method or a ramp-up/pulse
method for our in vitro selections. Two of the 50 compounds—
MMV028895 and MMV665824—were removed from the
selection study during experimentation. MMV665824 was
removed due to a signiﬁcant loss of potency, while MMV028895
exhibited cross-resistance to resistant parasites generated by
MMV007564. Out of the remaining 48 compounds, resistant
parasites were obtained for 23 (Supplementary Data 1). As each
selection was performed in triplicate with three independent
cultures, we succeeded in generating a total of 66 resistant
cultures. Parasites resistant to MMV026596 were not obtained
despite 100 days of selection, but the cultures acquired
hypersensitivity to meﬂoquine with a 10-fold reduction in EC50
compared with its parental line, 3D7. For the remaining 24
compounds, acquisition of resistant parasites was unsuccessful
despite numerous attempts over an extensive period of time.
To determine if the cross-resistance assay was predictive, we
sought to determine the target of MMV008149, the compound
resulting in the largest EC50 fold-shift (438 ) within the cross-
resistance assay set by fully sequencing six parasite clones that had
acquired resistance to MMV008149. The EC50 values for the
resistant lines ranged from 1.67mM to 10.06mM, a 3–21 EC50-
fold change when compared with the Dd2 parent (EC50¼ 485 nM).
Genomic DNA (gDNA) was isolated from the Dd2 parent and
six clones (two clones per resistant selection ﬂask), and samples
were prepared for whole-genome sequencing. Samples were
sequenced to460 coverage using paired end reads and aligned
to the 3D7 reference genome and variants were called with
HaplotypeCaller (GATK). Comparing the nucleotide variation
found in the resistant samples to the Dd2 parent clone, which had
been isolated immediately before selections, we identiﬁed
genomic changes that had presumably occurred during selection.
Following this comparison, 19 mutations were identiﬁed: 11
SNVs and eight insertion/deletions (INDELs) (Table 2,
Supplementary Data 2). INDEL mutations were comprised of
intergenic (three), codon INDEL (three), intronic (one) and
frame-shift (one) mutations. The SNV set showed a mixture of
intergenic (ﬁve), synonymous (three) and non-synonymous
(three) mutations. Comparing all six clones, one gene was
mutated across all samples: cytochrome bc1. Additionally, variant
positions correlated well to EC50 fold changes, with the lower fold
changes (3.4–5.9 ) corresponding to the G131S amino acid
change, and the higher EC50 fold-shifts (18–21 ) corresponding
to the Y126C and V284L amino acid changes. Two of the
mutations, G131S and Y126C, were contained in the Qo site,
while the third mutation (V284L) was not in either the Qo or Qi
binding region29. G131S was also the major mutation found in
CYTb-G131S, the cross-resistant strain predicting cytochrome
bc1 as a potential target for MMV008149. These results support
that the cross-resistance assay was able to successfully identify
compounds with overlapping targets, and made us more
conﬁdent that our compound set consisted of novel targets.
Multi-stage activity proﬁling. As drugs that eliminate multiple
stages of the parasite lifecycle will be critical components in global
Table 1 | Summary of mutated strains testing cross-resistance
Strain Target/pathway Parent strain SNVs References
ATQ-R4 cytb 3D7 M133I and L144S 15
ATQ-R5 cytb 3D7 F267V 15
CYTb-G131S cytb Dd2 G131S 16
CYTbQi cytb Dd2 G33A 17
GNF156R PfCARL Dd2 L830V, S1076I and M81I 14
NITD609-R2 PfATP4 Dd2 T418N and P990R 18
GNF449-R2 PfATP4 Dd2 I203L and P990R 19
PfATP4-Mut2 PfATP4 W2 P412L 20
PfATP4-Mut1 PfATP4 W2 V178I Unpublished
PfATP4-Mut3 PfATP4 3D7 F917L 20
TM90C2A DHFR (folate pathway) 3D7* Unknown (MR4 origin) 28
PfCRT-Q352R PfCRT Dd2 Q352R 29
DHODH DHODH 3D7 E182D 30
hsp90 cellular chaperone Dd2 D88Y Unpublished
ProRS prolyl t-RNA synthetase Dd2 L482H 31
*For TM90C2A, there was no ofﬁcial parent strain, so the clone was compared with 3D7 sensitive strain for cross-resistance.
Fifteen mutated strains and their respective parents were used to test for potential cross-resistance present in our compound panel. Mutations (SNVs) responsible for resistance are listed for each strain,
along with their corresponding parents and origin.
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efforts to eliminate malaria10, we were interested in knowing
whether the compounds in our study had additional activities
against either the liver and/or transmission stages of the parasite
lifecycle. To determine this, we ﬁrst evaluated the compounds in
additional phenotypic assays. The ﬁrst assay was a P. berghei
hepatocyte invasion and development assay, which predicts
causal prophylactic activity. Hepatocyte toxicity was additionally
tested to identify false-positive activity in the liver stage due
to host-cell toxicity. Assays were executed in duplicate using a
12-point EC50 curve at starting concentrations of 5mM or
50mM (Supplementary Table 1). Positive and negative
controls testing for hepatocyte toxicity and liver stage
activity included atovaquone (PfLuc EC50:0.419±0.044 nM;
HepG2 EC50:7720±1370nM) and puromycin (PfLuc EC50:
32.7±29.7 nM; HepG2 EC50:254±36.6 nM). Of the 47
compounds examined, 15 were found to be active against
liver-stage parasites (EC50 values o1mM (10–880nM)), nine of
which demonstrated a minimal ﬁvefold difference between
parasite activity and hepatocyte toxicity (Supplementary Fig. 1).
Interestingly, six compounds were more potent in the liver stage
than in the asexual stage. The most signiﬁcant potency change was
seen with MMV019066, a propanamide, which had a reduction in
EC50 from 1.67mM to 0.31mM and previously demonstrated
cross-resistance with cytochrome bc1 alleles. This was expected
given that cytochrome bc1 inhibitors are highly active against liver
stages. MMV024038, a quinoline sulfonamide, also demonstrated a
reduction in EC50 from 228 nM to 10nM. This compound,
however, exhibited some hepatocyte toxicity (146 nM); thus the
indirect effects of the host-cell environment on parasite growth
could not be ruled out.
The second assay was a late-stage (stage V) gametocyte survival
assay, which predicts transmission-blocking activity. Assays were
executed in duplicate using a 12-point EC50 curve at starting
concentrations of 1.25 mM or 12.5 mM (Supplementary Table 1).
Positive and negative control compounds included puromycin
(0.61±0.11 mM) and atovaquone (4 12.50 mM), respectively. For
the late-stage gametocyte assay, 12 compounds resulted in EC50
values o1mM (260–990 nM), 50% of which overlap with the 15
compounds found to have activity in the liver-stage assay. Of the


















































































































































































































































































































Figure 2 | Cross-resistance fold shifts observed in compound set. (a) A total of 15 resistant strains were tested with each MMV compound to identify
potential pre-existing cross-resistance. Calculating the fold shifts between each clone and either a corresponding parent or a drug sensitive 3D7 strain
generated the heatmap. To normalize conferred resistance and sensitivity, the natural log of each fold shift is displayed. Fold shifts instead of raw data were
used as multiple assays were run with varying times and detection indicators. Incomplete cross-resistance assays are depicted in white. All assays were run
in triplicate. For one compound (BRD1095), a close analogue (BRD3444) was analysed for TM90C2A and PfATP4-Mut1–3. SMILEs for all compounds are
listed in Supplementary Data 1. (b) Chemical structures of the two MMV compounds (MMV009108 and MMV028038) with increased efﬁcacy against
one or more pfatp4 mutated clones. Both compounds displayed low structural similarity to a number of other known pfatp4 inhibitors. (c) Chemical
structures of the two MMV compounds (MMV019066 and MMV008149) with decreased efﬁcacy against one or more cytochrome bc1 mutated clones.
Atovaquone and decoquinate, two other cytochrome bc1 inhibitors, were structurally signiﬁcantly different.
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demonstrated hepatocyte toxicity 410 the liver stage
EC50. Unlike the liver stage, none of the compounds had
increased potency against sexual stage compared with the asexual
parasites, which was expected as previous literature has found
that most currently used antimalarials yield higher EC50 values
against late-stage gametocytes when compared with the asexual
stage EC50 (ref. 13). Five compounds, however, demonstrated
late-stage gametocyte EC50 values within a twofold range of the
asexual EC50 value.
Rate of killing assays. To identify whether selection success could
be predicted by compound speed of action, and to gain a greater
insight into the potential mechanisms of action, assays were
performed to test the killing rate (Supplementary Data 1)33. To
quantify the killing rate, viability time-course proﬁles for each
compound were compared with antimalarials known to have fast
(chloroquine), moderate (pyrimethamine) or slow (atovaquone)
rate of action. These rates were then compared with other
compound characteristics, including cross-resistance proﬁle,
selection success, potency and structural characteristics to
identify any possible trends. Overall, the compound set resulted
in a fairly even distribution of fast, moderate and slow speeds
(Fig. 3a), implying there was no bias in the phenotypic screens for
a particular killing rate. One compound’s rate of killing,
MMV666080, was unidentiﬁable due to compound availability.
No correlation was seen between compound structure and speed
of action. Additionally, there was no correlation found between
killing rate and compound potency against 3D7, nor between
potency and selection success (Supplementary Fig. 2).
Comparing the selection success rate to compound rate of
killing, we saw a signiﬁcant positive correlation (P¼ 0.0022)
between speeds of action and selection success, as determined by
a one-tailed Fisher’s exact test. (Fig. 3b,c). Of the 12 selections
with compounds demonstrating a slow speed of action, 83%
(10/12) were successful. This was in contrast to compounds with
fast-killing rates of which only 26% (5/19) were successful.
Additionally, within each set of successful selections, we noticed a
trend within the length of time to generate resistant parasites. For
the fast-acting compounds, 3/5 successful selections took 4125
days, whereas 5/10 resistant parasites were successfully selected
for within 50 days for slow-acting compounds. Therefore, slower
compounds typically had greater success and required shorter
periods of time to develop resistance when compared with
fast-acting compounds. This trend remained relatively consistent
within individual labs. These results conﬁrm previous ﬁndings
of faster acting compounds having a lower propensity for
developing de novo resistance34. Fast-acting compounds are
already desirable in the clinic due to a quick clearance of parasites
and alleviation of symptoms, as well as their propensity towards
slower drug resistance development. The inability to develop
resistance in vitro, however, even when using slow ramp-up













Genome coverage (x) 84.13 81.56 74.81 90.93 82.73 72.93
% Covered by 15 or more reads 95.6 95.7 95.6 95.7 95.8 95
SNVs identiﬁed
Total mutations 3 3 5 1 4 4
Intergenic 0 2 4 0 1 3
Intronic 0 0 0 0 0 0
Synonymous 2 0 0 0 2 0
Non-synonymous 1 1 1 1 1 1




Total mutations 6 0 1 2 1 1
Intergenic 1 0 1 2 0 1
Intronic 1 0 0 0 0 0
Frame shift 1 0 0 0 1 0
Codon INDEL 3 0 0 0 0 0
Genes mutated in all samples
(mutation)
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Figure 3 | Killing rate trends. (a) Proportion of fast (CQ), moderate
(PYR or PYR/CQ), and slow (ATQ) compound killing rates in our compound
set (49 compounds in analysis). (b) Proportion of failed and successful
compound selections sorted by killing rate (47 compounds in analysis).
(c) Successful selections further proportioned out based on amount of time
required to result in resistant parasites. Trend in selection success and
killing rate was found to be statistically signiﬁcant (P¼0.0022) by a
one-tailed Fisher’s exact test.
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selection methods may imply that these beneﬁts come from the
target itself. These genes may have minimal mutational ﬂexibility
or inhibitors may target several genes, making them ideal for
exploitation in antimalarial development. Alternatively, some
compounds may have human host targets instead of parasite
targets and affect the erythrocyte directly. Further work is
required to distinguish between these possibilities.
Discussion
Every therapeutic, whether for the treatment of infectious
agents or malignant tumours, is in a race against time; a race
against the inevitable development of drug resistance leading to
reduced clinical effectiveness. Many factors play a role
in the development of resistance, from evolutionary and
biochemical constraints of the targeted organism to therapy
regimens and the overuse or misuse of therapeutics. Not all
therapeutics, however, are created equal. A detailed under-
standing of a targeted organism’s biology and the critical factors
required to minimize the emergence of resistance provide
opportunities to design more effective and long-lasting drugs
and drug combinations. This requires an extensive knowledge of
the organism, as well as a comprehensive understanding of how
resistance evolves.
This study represents the ﬁrst systematic analysis of cross-
resistance in malaria parasites. We have assessed 50 antimalarial
compounds with diverse chemical structures, rates of parasite
killing and stage speciﬁcity. With few exceptions, the compounds
studied did not demonstrate signiﬁcant cross-resistance
to previously identiﬁed targets, indicating a large potential to
identify additional druggable pathways in the parasite and further
our arsenal of antimalarial therapeutics. A lack of cross-resistance
to known drug targets does not mean that resistance will not
quickly develop, however, and the resistance ‘life expectancy’ and
resulting ﬁtness costs need to be considered for any potential
clinical candidate. In selecting for resistant mutants, we found
that fast-acting compounds are harder to develop resistance
against and generally have a longer onset of resistance when
compared with slow-acting compounds. Given that compound
killing rates are thought to be determined primarily by their
mode-of-action, this resistance feature may be largely due the
target or targets themselves. Moving forward, it will be important
to verify if this trend holds in compounds with multi-stage
activity, as only a small fraction of our compounds (6/50)
demonstrated activity against asexual, sexual and liver stage
parasites, and multi-stage active antimalarials will be vital in
achieving malarial elimination. In addition to killing rate, our
compound set provides a list of various physicochemical and
structural features that may additionally be predictive of selection
success, and the addition of our set to future screens may provide
an eventual predictive model, focusing on compounds less likely
to be prone to resistance development (Supplementary Figs 3 and
4). Fast-acting compounds have already been a focus in
therapeutic development as they rapidly stop disease progression
and avoid severe complications, but the additional beneﬁt of
reduced evolution of resistance makes them even more attractive
candidates for future antimalarial designs.
Methods
Compound origin and computational clustering. Compounds were all publically
available and obtained from a variety of sources, including the medicines for
malaria venture (MMV) malaria box10, the GlaxoSmithKline Tres Cantos
Antimalarial Set11, the University of Dundee and the Broad Institute’s Diversity
Oriented Synthesis libraries, as indicated in Supplementary Data 1. Compound
similarity was calculated using the ﬂexible MCS (FMCS) ﬁnder package in R.
Clustering was conducted using hclust with a ward.D2 method setting. Pairwise
distances were calculated between Tanimoto coefﬁcient values from fmcsR.
Strain culture origins and propagation. P. falciparum parent strains 3D7 and
Dd2 used for selection were obtained from the labs of Dan Goldberg and
David Fidock, respectively. The Fidock lab additionally supplied the Dd2Dexo
strain for selections with MMV000787 and MMV023367. Functional assay and
cross-resistant strains were obtained from the labs of Elizabeth Winzeler, Dyann
Wirth, David Fidock and GlaxoSmithKline, as listed in Table 1.
Asexual parasites were grown with 5% haematocrit at 37 C in RPMI (Rosewell
Park Memorial Institute)-1640 medium supplemented with 0.014mgml 1
hypoxanthine, 38.4mM HEPES, 0.2% NaHCO3, 0.2% glucose, 3.4mM NaOH,
0.3 g l 1 glutamine and 5% AlbuMAX II. Depending on lab preferences, parasites
were grown either in the presence or absence of 0.05mgml 1 gentamicin and 4.2%
human Oþ serum (Interstate Blood Bank, Inc.). Cultures were maintained in a gas
mixture of 5% O2, 5% CO2 and 90% N2. When not undergoing selections, cultures were
maintained with media changes every other day, keeping parasitemia values at 0.3–4%.
Frozen stocks were prepared using one of two methods: (1) by freezing 100%
red blood cells (RBCs) at B5% parasitemia with equal volumes of a freezing
solution composed of 28% glycerol, 3% sorbitol and 0.65% NaCl; (2) freezing 0.2ml
RBCs at B5% parasitemia with 0.3ml serum and 0.5ml of a glycerol solution.
Stocks were thawed out by slowly adding 1/5 volume of 12% NaCl, followed by ﬁve
volumes of 1.6% NaCl. Parasites were then spun down at 800g for 5min at room
temperature and washed with supplemented media before standard culturing
methods.
Cross-resistance and functional assays. EC50 assays were conducted using either
a 48 or 72-h assay based on lab preference and specialty (internal assay variance
summarized in Supplementary Fig. 5). The 48-h assay was carried out in a 96-well
format following standard methods using the 3H-hypoxanthine incorporation
assay35. The raw EC50 values corresponding to this assay can be found in
Supplementary Data 3. Brieﬂy, this assay relies on the parasite incorporation of
labelled hypoxanthine that is proportional to P. falciparum growth. A culture of
parasitized RBCs (0.5% parasitemia with a percentage of ring stage higher than
70% of total parasitemia, 2.0% haematocrit) in RPMI-1640, 5% AlbuMAX
and 5 mM hypoxanthine was exposed to drug serial dilutions. Plates were
incubated for 24 h at 37 C, 5% CO2, 5% O2 and 90% N2. After 24 h of incubation,
3H-hypoxanthine was added and plates were incubated for an additional 24-h
period. After that, parasites were harvested on a glass ﬁbre ﬁlter using a TOMTEC
Cell Harvester 96. Filters were dried and melt-on scintillator sheets were used to
determine the incorporation of 3H-hypoxanthine. Radioactivity was measured
using a microbeta counter. Data were normalized using the incorporation of the
positive (parasitized RBCs without drug) and negative (same culture with
artesunate at 2 mM) controls. All assays were conducted in triplicate using three
independently grown cultures, and EC50 values were determined using the XLﬁt
add-in module for Excel (version 2.3.1) from Graﬁt (version 5.3.1.3), where
parameter h is the assay hill slope, x is the compound concentration and y is the
inhibition of growth effect. The XLﬁt equation is:
y¼ ½ð100Þ= 1þ EC50=xÞh
  i
Additionally, any EC50 outliers were removed using a single iteration of Grubbs’
test, eliminating values with z-scores above the critical z-value (a¼ 0.05).
Alternatively, a SYBR Green-based proliferation approach was used for the 72-h
assay, as previously described32. Brieﬂy, a culture of either synchronized or
asynchronous parasitized RBCs (0.3% parasitemia and 4% haematocrit) in
screening medium (identical to supplemented medium above except no serum was
added) was exposed to serial drug dilutions. Plates were incubated at 37 C and
gassed with 93% N2, 4% CO2 and 3% O2 for 72 h. Following incubation,
10 SYBR Green I (Invitrogen; supplied in 10,000 concentration) in lysis buffer
(20 nM Tris-HCL, 5mM EDTA, 0.16% Saponin wt per vol and 1.6% Triton X vol
per vol) was added to the wells and the plates were incubated overnight at room
temperature before plate reading. EC50 assays were repeated three times, taking the
average EC50 value from each assay set, and removing any outliers using a single
iteration of Grubbs’ test, eliminating values with z-scores above the critical z-value
(a¼ 0.05). The raw EC50 values for synchronized parasites assayed in a 384-well
format are listed in Supplementary Data 4. The raw EC50 values for asynchronous
parasites assayed in a 96 or 1536-well format are listed in Supplementary Data 5.
EC50 values for each strain were compared with those of the corresponding
parent strain to determine fold-shift changes and identify resistance. To minimize
the cause variance between assays, all comparisons were conducted between strains
assayed under identical conditions. A one-way ANOVA followed by a Dunnet’s
post-test was conducted in GraphPad Prism to identify signiﬁcant changes between
the parent and resistant strain. For the purposes of this study and to minimize false
positive, compounds displaying 45-fold EC50 shifts and determined to be
signiﬁcantly different from its corresponding parent by a one-way ANOVA
analysis were identiﬁed as having potentially non-novel targets.
Cross-resistance computational analysis. Computational analysis of cross-
resistance was conducted in R. Brieﬂy, EC50 fold shift ratios were calculated using
log transformed EC50 values from the parental and resistant strains. As EC50 assays
were run across multiple labs, any strain fold-shift calculations were conducted
between strains run within the same lab to minimize error due to assay variability.
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The natural log of the ratios was loaded into R, and a heatmap analysis was
executed using heatmap.2 from the gplots package. Compounds were clustered by
structural similarity (fmcsR) and strains were clustered by column mean values.
Evolution of compound-resistant lines. Based on the compound speed of action
and lab specialty, selections were conducted using a high-pressure intermittent
selection method, a step-wise selection method, or a constant selection method. For
high-pressure selections, B1–2 109 parasites were treated at a concentration of
3–10 EC50 until parasites could not be seen by microscopy (4–10 days).
Following treatment, compound pressure was removed and cultures were allowed
to recover. Once healthy parasites were seen and parasitemia reached B2%,
compound pressure was reinstated. For step-wise selections, B1 108 parasites
were treated at a starting concentration resulting in a reduced growth rate of 50%.
Cultures were examined daily by microscopy, increasing compound concentration
in increments of 5–10% as needed to maintain a 50% reduced growth rate.
Selections were carried out until cultures achieved a reproducible EC50 fold shift of
43 . Finally, constant selections were conducted in a similar manner to the high-
pressure intermittent method with the exception that compound pressure was
never removed. Following successful selection, cultures were cloned out using a
limiting dilution method as previously described36. Selections were terminated after
200 days if resistance could not be obtained.
Library preparation and analysis of sequenced samples. gDNA was obtained
from parasites by washing infected RBCs with 0.05% saponin and isolating the
gDNA using a DNeasy Blood and Tissue Kit (Qiagen), following the standard
protocols. To prepare the sequencing libraries, gDNA was tagmented and ampliﬁed
with the Nextera XT kit (Cat. No FC-131–1024, Illumina) using the standard dual
index protocol, and sequenced on the Illumina HiSeq 2500 with a RapidRun mode,
sequencing 100 base pairs deep on either end of the fragments. Following
sequencing, reads were aligned to the P. falciparum 3D7 reference genome
(PlasmoDB v. 13.0), following the Platypus pipeline as previously described, with
the exception that SNVs and INDELs were called with GATK’s HaplotypeCaller37.
To identify valid variants, mutations were ﬁltered using general recommendations
from GATK (Supplementary Table 2). Following the initial ﬁltration, mutations
where read coverage were o5 and/or where mixed read ratios were40.2
(reference/total reads) across all samples were removed.
Rate of killing and multi-stage activity assays. Rate of killing was determined
for each compound following a previously described methodology, which uses the
invasion of fresh erythrocytes as surrogate of parasite viability33. Brieﬂy,
parasites were treated with compounds for 48 h. Compound was washed out and
fresh-labelled erythrocytes added to the treated parasites. Double stained
erythrocytes (RBC label plus parasite DNA label) were quantiﬁed and per cent of
survival determined.
Liver-stage activity was determined by pretreating hepatic human cells (HepG2)
for 2 h with compound in 1,536-well plates infected with freshly dissected
P. berghei sporozoites. After 48 h of incubation, the viability of P. berghei
exoerythrocytic forms was measured by luminescence reaction light output using
BrightGlo (Promega). Varying levels of compound concentration were used
(5mM or 50mM) due to the stock concentration supplied.
To test sexual-stage activity, compounds were tested against late-stage
gametocytes using a MitoTracker ﬂuorescent-based assay13. Speciﬁcally,
synchronized stage V gametocytes were incubated with compound for 72 h.
MitoTracker Red CMXRos (Life Technologies) was added to each well (ﬁnal
concentration: 500 nM) together with saponin to lyse the RBCs. Each plate was
then imaged with an Operetta High Content Imaging System (Perkin Elmer) for
ﬂuorescence (590–640 nm). Varying levels of compound concentration were used
(1.25 mM or 12.5 mM) due to the stock concentration supplied.
The gametocytocidal activity was measured using high-content image analysis
software (Harmony, Perkin Elmer). The readout was based on number of
metabolically active gametocytes per well.
Cheminformatics predictors. We evaluated the association between acquisition of
drug resistance and pharmacological, physicochemical and structural characteristics
of the 48 compounds for which selection was attempted. Speciﬁcally, we considered
the following properties: (1) pharmacological properties measured in this study:
killing rate, toxicity and EC50 at three different stages of parasite development; (2) 51
physicochemical descriptors obtained with QikProp software38 and 129 descriptors
obtained with VolSurfþ (ref. 39); and (3) 2,694 extended-connectivity ﬁngerprints
that encode circular substructures with a bond diameter of 10, generated by
ChemAxon software (ChemAxon, Kft.)40; and (4) 194 hierarchical scaffolds
associated with the compounds generated by HierS software41.
For each feature, we measured statistical signiﬁcance of its relationship to the
selection success, taking into account the nature of the features42. In particular,
structural features (that is, extended-connectivity ﬁngerprints and scaffolds) are
binary and indicate the presence or absence of each structural element in a
compound. For these reasons, hypergeometric statistical tests were applied to
structural features and t-tests were applied to pharmacological and physiochemical
features to measure statistical signiﬁcance.
Data availability. All 66 resistant P. falciparum lines will be deposited to the
Malaria Research and Reference Reagent Resource Center (MR4) and will be made
available on request to E.A.W. All relevant sequence data have been deposited in
the National Center for Biotechnology Information (NCBI) Sequence Read Archive
database with accession code SRP069308. The authors declare that all other data
supporting the ﬁndings of this study are available within the article and its
Supplementary Information ﬁles.
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